Ignite Creation Date:
2024-05-05 @ 7:30 PM
Last Modification Date:
2024-10-26 @ 9:50 AM
Study NCT ID:
NCT00687323
Status:
COMPLETED
Last Update Posted:
2017-06-07
First Post:
2008-05-27
Brief Title:
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia AML and Myelodysplastic Syndrome MDS Participants With Low O6-Methylguanine Methyltransferase MGMT Expression P05052
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Phase II Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia AMLMyelodysplastic Syndrome MDS Subjects Unsuitable for Standard Induction Therapy Exhibiting Low MGMT Expression
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TALL
Brief Summary:
The primary objective of this study is to evaluate the safety tolerability and efficacy of temozolomide in acute myeloid leukemia AML and myelodysplastic syndrome MDS participants who are not candidates for standard induction therapy and exhibit low MGMT expression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-7365-240 | None | None | None |